Antioxidants (2023) 12(2):514
For all four peptides on Thursday's agenda BPC-157, TB-500, KPV, and MOTS-C FDA staff reviewed the evidence under the agency's four-part balancing test and reached the same conclusion for each: do not add them to the 503A Bulk Drug Substances List, the only legal pathway for compounding pharmacies to dispense these compounds to patients
In particular, they observed that the percentage of eryptotic cells was significantly higher in patients with HB-ACLF in comparison with healthy donors, patients with chronic hepatitis B, and patients with cirrhosis
Melatonin, human aging, and age-related diseases
Mallampalli, PhD Key Takeaways: Compounded or counterfeit tirzepatide is not verified for safety, effectiveness, or quality, increasing the risk to patients since it is not FDA-approved